EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 120 filers reported holding EAGLE PHARMACEUTICALS INC in Q2 2015. The put-call ratio across all filers is 4.58 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $227,000 | -5.8% | 3,806 | +24.4% | 0.21% | -3.7% |
| Q2 2017 | $241,000 | -4.7% | 3,060 | +0.3% | 0.22% | -12.6% |
| Q1 2017 | $253,000 | -18.4% | 3,050 | -21.9% | 0.25% | -24.5% |
| Q4 2016 | $310,000 | +2.6% | 3,905 | -9.4% | 0.33% | +9.7% |
| Q3 2016 | $302,000 | +38.5% | 4,310 | -20.0% | 0.30% | +150.4% |
| Q1 2016 | $218,000 | -54.1% | 5,388 | +0.6% | 0.12% | -49.1% |
| Q4 2015 | $475,000 | +19.6% | 5,358 | 0.0% | 0.23% | +9.3% |
| Q3 2015 | $397,000 | -2.9% | 5,358 | +6.1% | 0.21% | +17.6% |
| Q2 2015 | $409,000 | -18.2% | 5,052 | -57.6% | 0.18% | -17.6% |
| Q1 2015 | $500,000 | – | 11,925 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |